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INTRODUCTION TO THE PANEL DISCUSSION
There is a need for prevention of cytomegalovirus infection. This is easiest tojus-
tify in the case of congenital infections with CMV that lead to severe congenital ill-
nesses. In addition, the reactivation type ofCMV infection has become increasingly a
problem in persons who receive organ transplants and immunosuppressive therapy.
One of the more striking situations is in bone-marrow transplantation where the
recipients often die of interstitial pneumonitis 2 to 4 months after successful trans-
plantation (4). This pneumonitis is strongly associated with and may be caused by
CMV infection (5). Finally, there may be milder but nevertheless important con-
genital defects such as late onset ofdeafness or mild mental retardation initiated by
CMV infection in utero, and there are other illnesses associated with CMV infection
such as hepatitis, mononucleosis, and postperfusion syndrome. The majority ofCMV
infections are inapparent, and there is a good chance that we will come to recognize
other syndromes that are caused by CMV infection.
It is worth noting that those conditions commonly assumed to be due to reactiva-
tion oflatent CMV infection have in most cases not actually beenproven to bedue to
reactivation; it has not been excluded that exogenous reinfection may play a role in
some such cases.
Let us consider some of the factors that are likely to bear upon the approach to
prevention ofinfection. First, reactivated infection presents quite a different problem
in terms of what is required to prevent it than does primary infection. Primary infec-
tion is due to exogenous virus, whereas truly reactivated infection as opposed to rein-
fection with a different strain is due to endogenous virus. It is obvious that we can ex-
pect that the latter type ofinfection will be more difficult to abrogate than the former
type.
A second important consideration would be the source or mode of transmission
of infection. Virus might be spread by the respiratory or the venereal route, and this
natural means of spread might be easier to prevent than infection transmitted by
infected cells or cell-associated virus, for example, through transfusion or organ
transplantation. Circulating antibodies should protect against the former but not
against the latter mode ofinfection. Herpesviruses can spread from cell to cell in the
presence ofneutralizing antibodies.
A third consideration is the significance ofcirculating CMV antibodies. Are they in
fact protective? Infection with cytomegaloviruses is not at all like infection with
poliovirus and other infections in which immunization, especially active immuniza-
tion, has been used successfully. Dr. Ho alluded to this point earlier. To indicate the
complexity of the situation, in those very bone-marrow recipients who are dying of
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interstitial pneumonitis, presumed although not yet proven to be due to CMV infec-
tion, extraordinarily high titers of CF antibodies are often found (4). This fact alone
tells us that we need to know a great deal more about the interplay between cellular
and humoral immunity at work in symptomatic CMVinfection.
Keeping these considerations in mind let us discuss the immunization procedures
that might be feasible. First of all, let us consider passive immunization. We can an-
ticipate that some protection could be achieved against primary infection with the
use of CMV antibodies that are passively acquired. This I say because of the
experience with Varicella-Zoster infections in which there is some evidence of pro-
tection (1). But this means of prevention might not work against reactivated infec-
tion. This mode of immunization might at least be tried during limited high-risk
periods, again for example in the recipients of bone-marrow transplants. Indeed
Neiman has proposed to use anti-thymocyte and anti-CMV globulin preparations in
this situation (5). This combination is to counter thegraft versus host reaction as well
as provide a high level of CMV antibodies. Appropriate globulins could be prepared
from animals that are inoculated with human thymocytes or T-cell lines and also im-
munized with purified cytomegalovirus. This is a special situation.
The reservation that passive immunization would have any merit at all comes in
part from the fact that mothers who have CMV antibodies do give birth to infants
who presumably have maternal antibody but nevertheless acquire neonatal and even
congenital infection according to observations made by Alford's group (8). There are
other grounds for reservations whether this approach would work in preventing
CMV infection, but a trial could be evaluated ifproperly conducted and should do lit-
tle or no harm.
Active immunization opens a number of other possibilities. One is the use of a
killed virus vaccine. This approach has not been effective or successful with herpes
simplex virus nor with poxvirus vaccines. In fact, with measles virus the use ofkilled
vaccine has actually proven to be hazardous. This is probably because the identity of
the protective antigen in the virus is not really known and is likely to be lost during
processing of the vaccine, as well as because ofthe heterogeneity ofvirion antigens as
brought out later. Also, killed virus vaccines are probably not as effective at stimulat-
ing cell-mediated immunity.
Another possibility, still in the future, would be the use of so-called subunit vac-
cines consisting offractions ofthe protein coat. Such preparations would be ofcourse
preferable to killed virus vaccines in that the viral genome could be eliminated so that
there is no possibility of phenomena such as multiplicity reactivation. There would
also be no defective genome that might be retained in cells. Indeed, it might be possi-
ble to dissociate the protective antigen from the putative sensitizing antigen and
preserve the protective activity in quantities that are still efficacious. This brings up
the other problem that we might have to deal with. We do not know whether there
are sensitizing antigens in the complex antigenic structure of CMV as apparently
exist in measles and rubella viruses, but there may well be. Certainly it would be de-
sirable to identify both sensitizing and protective components and to be able to
separate them.
The big problem with subunit vaccines is the quantity ofvirus required; certainly it
will be great, even once the identity of the protective components has been es-
tablished.
Now let's move on to consideration of attenuated virus vaccines. Theoretically,
such preparations would be ideal ifthey were possible to prepare with safety. The at-
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tenuated virus could be administered deliberately, produce asymptomatic infection,
and confer immunity that would be long lived, presumably life long.
There are many problems with this approach. Some of them have been en-
countered before, but some are newly posed by the herpes group ofviruses. The first
question is how do we attenuate cytomegalovirus? Does it really follow that passage
of the virus through human diploid fibroblastic cells leads to attenuation, and why do
we think that that is so? Mouse CMV becomes attentuated upon passage in mouse
cell culture, but once the virus has been inoculated in mice it becomes virulent again
(6).
The second point is related to the first. What is the index of attenuation that we
should use? Attenuation must exclude virulence in terms of clinical illness and con-
genital infection yet retain antigenicity in terms of humoral, cell-mediated, and local
immunity. Here we feel strongly the lack of an animal model for human
cytomegalovirus infections. There is no way to gauge the virulence of strains of
human CMV except in man.
The third point would be the strain differences that are now becoming well defined
among isolates of CMV. It is increasingly clear that we will find that immunization
with some strains of CMV would not provide full cross protection against certain
other strains, although there would be a degree of cross protection. This is being
brought out by the work of Huang as well as the earlier work ofWeller et al. (9). We
would have to be sure that we are dealing with key strains to generateimmunity.
The most important problem with the use of "attenuated" CMV strains both from
the theoretical side as well as the practical point of view arises from the habit of
herpes-group viruses of latency in man and other species. Biologically, these viruses
are unlike other viruses of man that have been used successfully in the preparation of
attenuated virus vaccines. The genome of cytomegalovirus as well as other herpes-
group viruses apparently persists for life after the initial infection. There is no reason
to think that an "attenuated" virus would not also produce persistent carriage of the
virus genome. We are then forced to consider not only whether the initial infection
with the vaccine virus is harmless and asymptomatic, but also what will happen when
that virus is reactivated. We know nothing about the relation, ifany, between degree
of symp oms upon primary infection and likelihood of serious or symptomatic reacti-
vated infection. It is almost certain that many silent primary infections do result in
symptoms, sometimes severe, during reactivation. I see no way at present to assess
this hazard in a risk versus effectiveness analysis. It would seem to be imperative that
we learn more about the epidemiology with respect to mode of transmission and the
pathogenesis of infections with CMV in man. It seems to me that with the herpes
group ofviruses this consideration must be more than a pious hope.
Related to this problem is the possibility, considered fairly remote but not ex-
cluded at present, that cytomegalovirus may have oncogenic potential (7). Any time
one introduces into human cells foreign DNA which remains capable of being
transcribed and translated, then the possibility that some portion of that genome
might code for a transforming factor or in some other way induce malignant change
has to be considered. Indeed it is well within the realm of biological possibility that
the selective process involved in attenuating a strain of virus might also select for a
more strongly oncogenic strain. Here we are doubly confounded because we have
markers neither for attenuation nor for oncogenicity ofCMV. I think itis premature
to work with such viruses in man until we have some reasonable basis of knowledge
on these points.
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Fortunately the outlook is not entirely bleak. The discovery by Huang of a
cytomegalovirus-induced DNA polymerase which is separable from hostcell
polymerases (2) and which can be specifically inhibited in tissue culture systems by
the antiviral compound, phosphonoacetic acid (3), offers quite another route apart
from immunization that offers real promise for control of cytomegalovirus infection.
Perhaps we will end up attempting to provide short-term protection against primary
infection with subunit vaccine to be usedin selected high-risk groups, let us say at the
time of pregnancy, and use antiviral substances during reactivated infections when it
is too late to attempt immunization.
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